Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) provides access to regulatory documents filed by LifeMD, Inc., the issuer of this preferred security. These filings, drawn from the SEC’s EDGAR system, include current reports on Form 8‑K and other disclosures that reference both the company’s common stock and its 8.875% Series A Cumulative Perpetual Preferred Stock.
LifeMD’s Form 8‑K filings illustrate how SEC reports can inform investors in LFMDP. For example, the company has filed 8‑Ks describing changes in its independent registered public accounting firms, including the dismissal of prior auditors, the identification of material weaknesses in internal control over financial reporting, and the appointment of PricewaterhouseCoopers LLP. Other 8‑Ks discuss the release of financial results for specific periods and the furnishing of related press releases as exhibits.
These filings also show how LifeMD reports broader corporate events that may be relevant to preferred stockholders. The company has disclosed the divestiture of its majority interest in WorkSimpli Software LLC, positioning LifeMD as a pure‑play virtual care and pharmacy platform, and has described its focus on expanding virtual care and pharmacy offerings. In addition, press releases incorporated into filings and separate company announcements detail quarterly cash dividends authorized on the 8.875% Series A Cumulative Perpetual Preferred Stock, directly affecting LFMDP holders.
Through this page, users can review LifeMD’s filed balance sheets, statements of operations, and related notes where the Series A Preferred Stock is presented within the capital structure, including information about authorized and outstanding shares. Current reports also reference the preferred stock explicitly in the context of material events and exhibit listings.
Stock Titan enhances this raw filing data with AI‑powered summaries that explain the key points of complex documents in plain language. As new LifeMD filings are posted to EDGAR, they are updated on this page, allowing investors to quickly see how changes in auditors, internal controls, financial reporting, corporate transactions, or dividend decisions might relate to LFMDP. Users can also review filings that touch on executive appointments, compensation arrangements, and other governance topics that shape the environment in which the preferred stock exists.
Pisano Christopher A reported acquisition or exercise transactions in this Form 4 filing.
LifeMD, Inc. reported that Chief Marketing Officer Christopher A. Pisano received a grant of 200,000 shares of common stock in the form of restricted stock units on March 30, 2026. The award carries no purchase price.
According to the vesting terms, 50,000 units vest on the grant date, and an additional 50,000 units also vest on the grant dateMarch 30, 2027. A further 50,000 units vest on March 30, 2027, with the remaining units vesting on March 30, 2028, aligning the compensation with continued service at the company.
LifeMD, Inc. executive Christopher A. Pisano, the company’s Chief Marketing Officer, filed an initial Form 3 as a reporting person. The filing lists no transactions or holdings, serving as a baseline disclosure of his status as an officer subject to insider reporting rules.
LifeMD, Inc. filed an initial insider ownership report on SEC Form 3 for Atul Kavthekar, who serves as Chief Financial Officer. The filing identifies him as a reporting person but shows no buy, sell, exercise, gift, tax-withholding, or other transactions, with all transaction counts and share totals at zero in this excerpt.
LifeMD, Inc. announced a planned Chief Financial Officer transition, with current CFO Marc Benathen departing to pursue a new opportunity and remaining through March 31, 2026 to support an orderly handover. He will then provide transition advisory services for six to twelve months for a $38,117 monthly fee and receive COBRA reimbursement through no later than April 1, 2027, while forfeiting any RSUs unvested as of March 31, 2026.
The company appointed Atul Kavthekar as its new CFO effective March 16, 2026, with a base salary of $500,000 and an annual performance bonus targeted at 50% of base salary. As a material employment inducement, he will receive 675,000 RSUs, split evenly between time-based vesting over three years and performance-based vesting tied to company targets.
LifeMD also expanded its leadership team by promoting Chris Pisano to Chief Marketing Officer and Jessica Friedeman to Chief Business Officer, reflecting a broader effort to align finance, marketing, and business development with the company’s next phase of growth.
LifeMD, Inc. reported strong 2025 growth, with full-year revenue up 25% to $194.1 million and adjusted EBITDA up 309% to $15.3 million. Fourth-quarter revenue rose 4% to $46.9 million, while adjusted EBITDA increased to $4.8 million, reflecting an 87% gross margin.
The business from continuing operations still posted a 2025 GAAP net loss of $10.2 million, but total net income reached $15.6 million including discontinued operations. LifeMD ended 2025 with $36.8 million in cash and no debt, supporting investment in GLP-1 weight management, Wegovy launches, and expanding women’s health offerings.
For 2026, LifeMD guides to revenue of $220–$230 million and adjusted EBITDA of $12–$17 million, with annualized run-rate revenue expected to exceed $250 million and run-rate adjusted EBITDA to exceed $25 million by Q4 2026.
Form 144 notice for proposed sale of securities. The filer intends to sell 75,000 common shares of the issuer through Charles Schwab (3000 Schwab Way, Westlake, TX) on 09/10/2025 on NASDAQ, with an aggregate market value of $459,000. The issuer has 47,417,393 shares outstanding. The 75,000 shares were acquired by RSU vesting from the issuer on 03/01/2025. No securities were sold by the selling person during the past three months. The notice includes the seller's representation that they possess no undisclosed material adverse information.
LifeMD insider stock award vested: The company's Chief Legal Officer and General Counsel, Eric H. Yecies, had a grant of 50,000 common shares vest on 08/22/2025. The report shows those shares were issued at a $0 per-share price as a performance-based award that vested.
Following this vested award the reporting person beneficially owns 388,900 shares of the issuer's common stock. The Form 4 discloses this as a non-derivative acquisition reflecting the conversion of a performance stock grant into common shares.
LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.
Maria E. Stan, Chief Accounting Officer of LifeMD, Inc. (LFMD), reported a non‑derivative acquisition of common stock that vested on August 22, 2025. The Form 4 shows a grant of 20,000 shares was recorded as acquired at a price of $0 and the reporting person now beneficially owns 227,500 shares. The filing is signed and dated August 26, 2025. No other transactions or derivative positions are reported.